TipRanks
Larimar Therapeutics, Inc. (DE:ZA71)
FRANKFURT:ZA71
Germany Market
ZA71
Larimar Therapeutics
RESEARCH TOOLSreports

Larimar Therapeutics (ZA71) Stock News & Sentiment

3 Followers
Larimar Therapeutics Appoints New President and COO
Premium
Company Announcements
Larimar Therapeutics Appoints New President and COO
11d ago
8K
LRMR
Larimar’s CTI-1601 Study Update Keeps Friedreich’s Ataxia Catalyst in Play
Premium
Company Announcements
Larimar’s CTI-1601 Study Update Keeps Friedreich’s Ataxia Catalyst in Play
1M ago
LRMR
Larimar’s Phase 3 Friedreich’s Ataxia Trial Puts Nomlabofusp in the Investor Spotlight
Premium
Company Announcements
Larimar’s Phase 3 Friedreich’s Ataxia Trial Puts Nomlabofusp in the Investor Spotlight
2M ago
LRMR
Larimar Therapeutics: Buy Rating Reaffirmed as FDA-Backed Nomlabofusp Progress Supports Unchanged $25 Price Target
Premium
Ratings
Larimar Therapeutics: Buy Rating Reaffirmed as FDA-Backed Nomlabofusp Progress Supports Unchanged $25 Price Target
2M ago
LRMR
Analyst Sees Larimar as Undervalued on Nomlabofusp’s Strong Efficacy and On‑Track BLA, Reiterates Buy Rating Ahead of 2027 FA Launch
Premium
Ratings
Analyst Sees Larimar as Undervalued on Nomlabofusp’s Strong Efficacy and On‑Track BLA, Reiterates Buy Rating Ahead of 2027 FA Launch
2M ago
LRMR
Regulatory and Manufacturing Risks Cloud Larimar Therapeutics’ Accelerated Approval Path for Nomlabofusp
Premium
Company Announcements
Regulatory and Manufacturing Risks Cloud Larimar Therapeutics’ Accelerated Approval Path for Nomlabofusp
2M ago
LRMR
Larimar reports Q2 results and nomlabofusp progress
Premium
Company Announcements
Larimar reports Q2 results and nomlabofusp progress
2M ago
8K
LRMR
More DE:ZA71 News >

ZA71 News on the Web

Larimar Therapeutics Names John Harlow As President And COO
rttnews
Neutral
Larimar Therapeutics Appoints New President and COO
TipRanks News
Neutral
Larimar Therapeutics appoints John Harlow as COO
TipRanks News
Bullish
Analyst Sees Larimar as Undervalued on Nomlabofusp’s Strong Efficacy and On‑Track BLA, Reiterates Buy Rating Ahead of 2027 FA Launch
TipRanks News
Bullish
Regulatory and Manufacturing Risks Cloud Larimar Therapeutics’ Accelerated Approval Path for Nomlabofusp
TipRanks News
Bearish
Buy Rating Reaffirmed on Growing Nomlabofusp Confidence; $25 Price Target Maintained
TipRanks News
Bullish
Larimar, Cytokinetics, Itau, Global-e, Immunovant Shake-Up
TipRanks News
Bullish
Insider Move: Larimar Therapeutics Director Makes Bold New Stock Purchase
TipRanks News
Neutral

News Score - Last 7 Days

Neutral
DE:ZA71
Sector Average
Media Buzz
This Week1 articles
Weekly Average1.25 articles
News Sentiment
This Week50%
Sector Average91%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is DE:ZA71’s Media Buzz Sentiment?
1 articles about DE:ZA71 were published this week. In an average week, 1.25 articles are published.
    What is DE:ZA71’s weekly average amount of articles?
    In an average week, 1.25 articles about DE:ZA71 are published.
      What is DE:ZA71’s News Sentiment?
      50% of articles about DE:ZA71 were positive this week, compared to its sector average of 91%.
        Healthcare Stocks that are Trending in the News
        CMXHFCSL
        RZLTRezolute
        AMGNAmgen
        PMCUFPro Medicus Limited
        ABTAbbott Laboratories
        Showing the stocks with the most bullish news sentiment over the past week